- Home
- CYTK vs DKNG Comparison
CYTK vs DKNG Comparison
Compare CYTK & DKNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYTK | DKNG |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.5B |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYTK | DKNG |
|---|---|---|
| Price | $76.84 | $25.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 31 |
| Target Price | ★ $89.26 | $38.10 |
| AVG Volume (30 Days) | 1.7M | ★ 13.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.05 |
| EPS | N/A | ★ N/A |
| Revenue | $13,368,000.00 | ★ $6,054,525,000.00 |
| Revenue This Year | $7.37 | $15.47 |
| Revenue Next Year | $310.19 | $13.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.99 |
| 52 Week Low | $34.60 | $20.46 |
| 52 Week High | $88.31 | $48.78 |
Technical Indicators
Market Signals| Indicator | CYTK | DKNG |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 54.91 |
| Support Level | $73.95 | $25.01 |
| Resistance Level | $79.66 | $26.86 |
| Average True Range (ATR) | 2.91 | 1.06 |
| MACD | -0.37 | 0.16 |
| Stochastic Oscillator | 33.77 | 89.40 |
Price Performance
Historical ComparisonAbout CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
About DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number-two or -three revenue share position across states where it competes. With its predictive market launch in 2025, DraftKings is now live with online or retail sports betting in most all states and i-gaming in five states, with both products available to around 40% of Canada's population. In 2025, sports revenue was 63% of total sales, i-gaming 30%, and fantasy and lottery 7%.